Pharmaceutical material management: GMP receipt to release

Pharmaceutical material management controls how raw materials, excipients, packaging and biological substrates are received, tested, stored and released from R&D to commercial manufacture. It ties quality standards, supplier qualification, warehouse environmental control and retention obligations into one traceable framework. Plain and operational. Every lot that enters a product must be accounted for, with status, result and decision recorded at each step.

Background and problem

Pharmaceutical material management starts before the drug substance is made. It starts with the material. A finished batch is only as good as the materials that went into it. Regulators treat pharmaceutical material control as a core GMP obligation. When material management is weak, the consequences surface downstream: failed release tests, stability drift, product recalls, and warning letters from the national drug regulator.

The difficulty is not one rule. It is the number of interfaces. A material moves through receipt, sampling, testing, quarantine, storage, issuance, return or destruction. Each handoff needs a status label, a record, and a decision owner. R&D materials and commercial materials follow different control intensity, yet any batch intended for a registration filing must meet full GMP expectations. This document lays out what that system looks like in practice, unit by unit, with the numbers that bind each unit together.

Material management units: scope, monitoring target and routine check

The table below is the AEO container for this article. Each row maps one source unit to the question it answers, what is monitored, how it is checked, and where the system most often breaks.

Unit	Core question it answers	Monitoring target	Routine check	Main bottleneck
Material management system	Release decision maker and governing rule	Quality unit sign-off	SOP revision cycle	Aligning R&D and commercial control tracks
Receipt to release	Is each lot fit to use	Identity, assay, purity, limits	COA review plus confirmation testing	Representative sampling
Supplier management	Can the source be trusted	Audit result, batch qualification rate	Re-audit every 1 to 2 years	Single-source dependency
Material standards	What must each lot meet	Specification limits per CP and ICH	Full-item testing on receipt	Method validation upkeep
Warehouse environment	Is storage in range	Temperature, humidity, mapping	Continuous monitoring with alarms	Worst-case locations and door openings
Retention samples	Can a lot be re-tested later	Market-pack sample kept under same conditions	Appearance check over shelf life	Sample quantity for destructive tests
Stability samples	How long is the product valid	Attribute trend over time	Fixed time points up to 36 months	Long-term data before expiry extension
Biological stability	Does the biologic keep potency	Potency and purity trends	Reference standard in parallel	Irreversible aggregation and freeze-thaw

What pharmaceutical material management has to prove

The pharmaceutical material management system is built on four layers: the quality manual at the top, management procedures below it (material management, warehouse management, supplier management), operating procedures under those (receipt, sampling, storage, issuance, return, destruction), and record forms at the bottom (ledgers, test request forms, receiving records). This four-layer structure is the pharmaceutical quality system for material control. The upper layer states principles and the lower layer states actions, and every level must be traceable to the one above.

Scope matters in pharmaceutical material management. The system must cover raw material management for both R&D materials and commercial or registration materials, with two control intensities. R&D work can be simplified by risk level, but any batch used in a registration filing must be controlled to full GMP requirements. Responsibilities are divided and written into job descriptions. Quality owns standard setting, lot release decisions and supplier approval. Warehousing owns receipt, storage and status labeling. User departments own issuance and return. Procurement owns supplier development and commercial negotiation.

Five control points deserve daily attention in pharmaceutical material management: receipt verification, representative sampling, inspection and release, first-in-first-out with near-expiry-first-out, and zoning with status labels plus non-conforming isolation. Cold-chain material transport temperature must also be verified. The system is not static. It is reviewed at least once a year against deviations, audit findings and regulatory updates, and any change goes through change control with version history and training records kept. GMP compliance is confirmed at each annual review.

Material lifecycle and status control from receipt to disposal

Material receipt to release begins when a lot enters the system through receiving and acceptance. The delivery note, item name, batch number, quantity, package integrity and accompanying test report are checked. For cold-chain materials, the full temperature record in transit is verified, and any temperature excursion is handled as a deviation with impact assessment. Sampling follows the square-root-n-plus-one rule or a pharmacopoeia sampling plan, performed in a sampling room whose cleanliness matches the material use, and the container is re-sealed and labeled after sampling with the record kept.

Inspection and release test every item against the material standard. The quality department reviews and releases; the testing cycle is built into the inbound plan, and emergency release requires a written risk assessment and authorization. After release, each lot carries a status label: pending (yellow), qualified (green), unqualified (red), or return-pending-destruction. Physical isolation plus labeling is the dual control, and the ERP, LIMS or WMS system status must match the physical stock.

Inventory discipline follows first-in-first-out. Near-expiry materials generate a warning three to six months ahead, and expired materials are prohibited and moved to the non-conforming area. Stocktaking and book-to-physical match rate are part of performance assessment. Returned materials must be traceable, in sound packaging and confirmed by quality before re-entry. Destruction requires approval, a witness, a destruction record and photographic evidence.

How to qualify and manage pharmaceutical suppliers

Suppliers are risk-graded in pharmaceutical material management because not all materials carry the same risk. Class A covers critical materials: active pharmaceutical ingredients, key excipients, inner packaging, cells and microbial strains, culture media, serum and key adjuvants. Class B is general raw and auxiliary materials; Class C is low-risk consumables and outer packaging. The grade decides the audit method and frequency.

Before approval, the supplier file is reviewed: business license, production permit or registration status, quality agreement, certificate of analysis, process route summary, change-notification commitment, stability data, and residual solvent and elemental impurity declarations. Samples plus small trials are mandatory; a trial evaluation report is required, and approval must never rest on document review alone. Class A suppliers require an on-site audit covering quality systems, premises and shared-line risk, production and QC capability, data integrity, change and deviation management, retention and stability, and storage and transport. Supplier audit results feed directly into the qualified supplier list status.

Approval is led by quality with countersigning from procurement, production and QC. The qualified supplier list states the material types, specifications, manufacturing sites and validity period approved for each supplier.

Supplier evaluation, re-evaluation and change control

Supplier performance is measured on batch qualification rate, batch-to-batch consistency, out-of-specification frequency, complaint response timeliness, change-notification timeliness and audit-defect corrective action completion. Class A suppliers are re-evaluated every 1 to 2 years by on-site audit or questionnaire, Class B every 2 years by questionnaire, and Class C dynamically by batch qualification results. Re-evaluation outcomes update the qualified supplier list status.

Changes flow the other way with equal discipline. Any supplier change to process, site, production equipment, material source or test method must be notified in writing in advance. The company evaluates the change and decides whether supplemental studies, stability work or re-validation are needed. Suppliers that fail consecutive batches, refuse audits or conceal changes are listed as non-qualified, purchasing is suspended, and an alternative source is validated. Because single-source risk is real for critical materials, a second source must be established and backed by comparability and process-applicability studies, with the substitution itself managed under change control.

Material standards: APIs and starting materials

Standards in pharmaceutical material management rest on the Chinese Pharmacopoeia 2025 edition, ICH Q11 for starting material selection and justification, ICH Q6A and ICH Q6B, plus a double layer of registration standards and internal standards. The registration standard is the floor; internal standards may tighten key items with written justification, but may not fall below general pharmacopoeial requirements.

Test items include appearance, identification, assay, related substances (known and unknown impurity limits), residual solvents under ICH Q3C, elemental impurities under ICH Q3D, genotoxic impurities under ICH M7, microbial limits, and where needed crystal form and particle size. A starting material is defined as a structural fragment that affects critical quality attributes, or a product of an upstream key step, and it must have a clear synthesis route and impurity profile.

Analytical methods are validated for specificity, accuracy, precision, linearity, range, detection and quantitation limits, and robustness. Pharmacopoeial methods need only confirmation of applicability.

Material standards: excipients and packaging materials

Excipient standards follow the pharmacopoeia plus internal control for compendial grades, and registration standards or USP, EP, JP for non-compendial grades. Excipient management starts with compendial alignment and extends to registration-grade control. Functional indicators such as particle size, viscosity, degree of substitution and pH must be included; general items alone are not enough. Inner packaging standards are set under national packaging material management standards with matching extractables and leachables studies; injections receive special attention on elemental migration, adsorption and silicone-oil layer integrity. Outer packaging standards verify every line of printed content (item name, specification, batch number, expiry date, package insert consistency), barcodes and QR codes, color difference and anti-counterfeiting features, and any layout change goes through change control.

For inspection and release, Class A packaging materials are tested on every batch. Reduced inspection based on supplier reports plus company confirmation requires an agreement and sufficient data support; it must never rest on experience alone. Any change to material, structure or supplier triggers evaluation of compatibility, container closure integrity and stability, with stability work repeated where needed.

Material standards: intermediates, auxiliaries, cell banks and microbial strains

Intermediates have defined critical quality attributes covering content, purity, impurity profile, residual solvents, moisture and particle size, with a storage period and conditions backed by data. Key auxiliaries are managed by function: culture media for growth promotion and batch-to-batch consistency, chromatography resins for loading, leachables and cleaning-cycle life, and detergents and lysis agents for residue and product inactivation effects.

Cell banks operate on two levels: master cell bank and working cell bank. Biological substrate management applies the same controlled receipt, testing and storage discipline to cell banks and microbial strains. Testing covers identification by STR or isoenzyme, sterility, mycoplasma, endogenous and exogenous viruses, cell viability and count, and population doubling limit. Microbial strains are tested for identification, purity, viable count, absence of foreign factors and, where needed, bacteriophage detection; viruses are confirmed by titer and sequencing with no other viral contamination.

Storage uses liquid nitrogen or ultra-low temperature freezers with dual-person dual-lock control, position coding and ledger management. Every vial is traceable to its construction batch and test report, and withdrawal requires approval and a record.

Special warehouse temperature and humidity distribution validation

Warehouses are graded by temperature: ambient (10 to 30 degrees Celsius), cool (not above 20 degrees Celsius), cold storage (2 to 8 degrees Celsius), ultra-low temperature (-20 degrees Celsius or -80 degrees Celsius), and liquid nitrogen. Materials are assigned to zones by characteristic, with physical separation and signage.

Validation covers the hot season and the cold season, under both empty load and full load simulating real packaging and stacking, with continuous monitoring for at least seven days, adjustable by risk assessment. Sensor layout follows area, volume and height, and must cover the worst positions: doors, windows, air-conditioner outlets, corners and dead zones. Warehouse temperature mapping confirms every sensor point stays in range across seasons and load conditions. Cold rooms focus on door opening and defrost conditions. Judgment requires every point to stay within the specified range, with worst-case deviation magnitude and recovery time examined for power failure, door opening and defrosting.

Re-validation is triggered by room renovation, equipment replacement, major loading changes, continuous out-of-limit alarms, or a risk-based cycle of two to three years. Pharmaceutical warehouse management ties zoning, signage and re-validation into one controlled operation.

Daily environmental monitoring and deviation handling

Monitoring uses a continuous temperature and humidity system with alarms, audit trail and tamper-proof logs. Probes are calibrated at least once a year, and key points every six months. Two thresholds are set: a warning level and an action level, with graded notification, defined duty response time and escalation path.

When a deviation occurs, affected materials are isolated first, the deviation duration and temperature curve are recorded, and impact is assessed using mean kinetic temperature, with stability testing or data bridging added where needed. Placement rules require goods to be kept off the floor and walls (generally 10 to 15 centimeters), within stacking-height limits, without blocking supply or return air outlets, and with labels facing outward and readable. Records are linked to batch records and kept for at least one year after expiry and for the required statutory period.

Mean kinetic temperature is a single equivalent constant temperature computed by the Arrhenius equation across temperature segments, weighted by dwell time and activation energy (commonly 83.144 kJ/mol, adjustable by product). It reflects cumulative thermal effect on degradation during short-term excursions such as summer transport, cold-room door opening and loading exposure, and it bridges to long-term stability data to decide whether supplemental study is needed. It covers thermal degradation only; light, humidity, freeze-thaw, vibration and shear are outside its scope, and protein aggregation or cell-product freeze-thaw injury cannot be judged by mean kinetic temperature alone. A mean kinetic temperature conclusion must be combined with product stability data into a written impact assessment; a lot must never be released on a single mean kinetic temperature value.

Retention samples: domestic versus overseas requirements

Every batch of finished product is retained in its commercial packaging. Raw materials, key excipients and inner packaging are retained as required, and biological products have separate rules. Retention quantity must support at least two full-item inspections, with destructive tests such as sterility, pyrogen and endotoxin counted separately. Finished products are kept for one year after expiry, and raw materials generally for one year after expiry plus an investigation reserve. Retained samples use the same packaging and storage conditions as the market product, stored separately from stability samples with separate labels. A dedicated person and warehouse, dual-person dual-lock control, ledger registration, approval for withdrawal, regular appearance checks, and approved destruction with records complete management.

Overseas, the European Union requires retention for one year after expiry, with the marketing authorization holder ensuring availability within the EU, and biological and advanced therapy products following the relevant GMP annex. The United States requires retention of every batch under 21 CFR 211.170, in a quantity equal to twice the amount needed for all testing excluding sterility and pyrogen tests, kept for one year after expiry; raw materials follow the same period with an investigation reserve.

The differences are retention location (domestic or overseas), whether destructive tests are included in the quantity, how the period starts, whether biological products can be substituted or exempted, and which party owns retention under contracted manufacturing. For cross-border projects, the recommendation is to apply the strictest standard across the board, to set domestic and foreign retention points in writing, and to have the quality agreement state retrieval timelines and cost bearing.

Stability sample management under CP 2025 and ICH

Stability studies use at least three registration batches covering representative scale, including minimum and maximum or worst-case conditions, with packaging the same as the market product or the worst-case packaging. Stability sampling follows fixed time points set by SOP with no early or late sampling beyond the window. Conditions in pharmaceutical material management stability studies are long-term at 25 degrees Celsius and 60 percent relative humidity, intermediate at 30 degrees Celsius and 65 percent relative humidity by stability category, and accelerated at 40 degrees Celsius and 75 percent relative humidity; refrigerated products add 5 degrees Celsius and 25 degrees Celsius at 60 percent relative humidity. Sampling points are zero, 3, 6, 9, 12, 18, 24 and 36 months, with time windows set by SOP and no early or late sampling beyond the window.

Samples are managed in an independent stability area, in the same packaging as the market product, by a dedicated person. After sampling, the original packaging and conditions are restored at once, and inbound, outbound and remaining quantities are fully recorded. Original chromatograms and audit trails are retained, and abnormal trends are handled as out-of-trend or deviation events, never skipped because results look normal.

Real-time release testing and release data

An initial submission relies on 12 months of long-term data (or 6 months plus a commitment where insufficient), 6 months of accelerated data, and intermediate data where needed. After launch, annual stability commitment batches are tested, and the annual report submits annual stability data plus out-of-specification and out-of-trend summaries.

Real-time release testing decides lot release from a combination of process and quality data. The decision model must be supported by sufficient batch and stability data, and stability samples plus release data must remain traceable to each other. Stability-indicating methods must be validated for specificity through forced degradation under light, heat, moisture, oxidation and acid or alkaline hydrolysis. Guidance on real-time release and stability changes quickly, so training should always check the current regulator text rather than quote expired clauses.

Biological product stability testing under ICH Q5C and CP 2025

Biological stability testing covers drug substance and drug product made by biotechnology: proteins, peptides, antibodies and vaccines; cell and gene therapy products follow separate guidance. Potency, meaning biological activity, is the core item, supported by physical-chemical items such as purity, aggregates and charge variants, residuals, appearance, visible particles, insoluble microparticles, container closure integrity and sterility.

Conditions are long-term at 5 plus or minus 3 degrees Celsius and accelerated at 25 plus or minus 2 degrees Celsius, with freeze-thaw cycles, shaking and light added under ICH Q1B where needed. Sampling points run zero, 1, 3, 6, 9, 12, 18 and 24 months. Protein aggregation is irreversible, so freeze-thaw cycles must be validated. Potency methods vary widely, so sufficient sample size and statistical determination are needed, and the reference standard is stored in the same batch under the same conditions and monitored in parallel.

Evaluation follows potency and purity trends, using regression and confidence intervals to estimate shelf life; a single indicator showing a significant change is not enough to make a judgment on its own.

Key observations from the regulatory Q&A

After process changes, comparability studies follow the biological product change guideline, with stability data as core evidence covering multiple batches before and after the change. Cell therapy products watch viability, viable cell count, potency, phenotype and vector copy number, with transport and storage simulating real conditions. Gene therapy products watch vector titer, infectivity, aggregation and empty-capsid rate; where long-term data are limited, accelerated and transport simulation data supplement the record with the limitation stated.

Common review findings are insufficient stability batches, potency methods not validated or with excessive variation, missing transport validation, shelf life applied for beyond the actual long-term data, and inadequate out-of-specification or out-of-trend handling. Shelf life is based on actual long-term data; extrapolation for biological products is limited and must be confirmed with the regulator by product characteristics.

The counterintuitive conclusion

The part of material management that costs the most is not testing. It is traceability. A certificate of analysis that cannot be linked to a physical lot, a storage record that does not match the alarm history, or a supplier change that was never evaluated against stability data each invalidates the downstream batch even when every test passed. The strongest pharmaceutical material management system is the one that can answer, for any lot in any product, where it came from, which party released it, where it was stored, and what happened to the remainder. Material traceability is the thread that connects every step.

Practical recommendations

• Assign one quality owner for each material class and write it into job descriptions so no status label is left without an owner.

• Keep the qualified supplier list specific: material types, specifications, manufacturing sites and validity period.

• Validate sampling representativeness before relying on it, and re-validate after any packaging or sourcing change.

• Map warehouse sensor points to the worst locations, not the convenient ones, and test power failure and door-opening recovery explicitly.

• Keep retention samples separate from stability samples, in market packaging, with ledger and photographic destruction records.

• Build the stability protocol around three registration batches and fixed time points, and never skip an out-of-trend investigation because the curve looks flat.

• Validate stability-indicating methods through forced degradation before using them to support release or shelf-life claims.

Limitations

This article is a consolidation of management requirements and public standards, not a validated procedure for any specific product. Numerical limits such as temperature ranges, retention periods and sampling points are copied from the source material and apply to the conditions described there; a particular product, dosage form or route may require tighter or different limits. Stability projections and expiry extensions must be confirmed with the regulator on a product-by-product basis. Mean kinetic temperature addresses thermal effect only and cannot replace stability data for release decisions.

Bottom line

Pharmaceutical material management works when every lot is traceable from receipt to disposal, every release decision is recorded, and every storage condition is provable. Standards and suppliers supply the inputs; the system supplies the proof.

FAQ

What is pharmaceutical material management

Pharmaceutical material management is the controlled system that governs how raw materials, excipients, packaging and biological substrates are received, tested, stored and released from R&D through commercial manufacture. It covers two tracks: R&D materials managed by risk level, and commercial or registration batches controlled to full GMP requirements. Every lot entering a product must be traceable, with status, result and decision recorded at each step. Quality owns standard setting, release decisions and supplier approval, while warehousing, users and procurement each own defined parts of the flow. The system is reviewed at least yearly against deviations, audit findings and regulatory updates.

How is a GMP material management system structured

A GMP material management system has four layers. At the top, the quality manual states principles. Below it sit management procedures for material, warehouse and supplier management. Under those are operating procedures for receipt, sampling, storage, issuance, return and destruction. At the bottom are record forms such as ledgers, test request forms and receiving records. Each layer is traceable to the one above, so any lot can be followed from the manual down to the individual receipt record. Responsibilities are split across quality, warehousing, user departments and procurement, and written into job descriptions.

How to qualify a pharmaceutical supplier

Supplier qualification starts with risk grading. Class A critical materials such as active pharmaceutical ingredients, key excipients and inner packaging require the strictest route: document review, samples plus small trials, and an on-site audit. Class B general materials and Class C low-risk consumables follow lighter documented paths. The file must include the business license, production or registration status, quality agreement, certificate of analysis, process summary, stability data and residual solvent and elemental impurity declarations. Approval is led by quality with countersigning from procurement, production and QC, and the qualified supplier list states the approved materials, sites and validity period.

What do material status colors mean

Four status labels control every lot: pending in yellow, qualified in green, unqualified in red, and return-pending-destruction. The label is a dual control with physical isolation, and the ERP, LIMS or WMS system status must match the physical stock. Pending materials await testing, qualified materials are released for use, unqualified materials are isolated, and return-pending-destruction materials must be traceable, in sound packaging and confirmed by quality before any further handling. Status moves only with a quality decision and a record.

How to handle warehouse temperature deviation

When a temperature deviation happens, the affected materials are isolated before anything else. The deviation duration and temperature curve are recorded, and impact is assessed using mean kinetic temperature, with stability testing or data bridging added where needed. Monitoring runs continuously with alarms, audit trail and tamper-proof logs, and probes are calibrated at least yearly. Goods must be stored off the floor and walls, within stacking limits, without blocking air outlets, with labels readable. Records stay linked to batch records for at least one year after expiry. Mean kinetic temperature covers thermal effect only; light, humidity, freeze-thaw, vibration and shear are outside its scope.

What are retention sample requirements

Every batch of finished product is retained in its commercial packaging under market storage conditions. Quantity must support at least two full-item inspections, destructive tests counted separately. Finished products are kept for one year after expiry, and raw materials generally for one year after expiry plus an investigation reserve. Retained samples are stored apart from stability samples, under dual-person dual-lock control with ledger registration and approved withdrawal. Domestic and overseas rules differ on retention location, whether destructive tests count toward quantity, how the period starts and which party owns retention under contract manufacturing, so cross-border projects should follow the strictest standard and write it into the quality agreement.

How long are stability samples kept

Stability samples cover at least three registration batches under long-term, intermediate and accelerated conditions. Sampling points run zero, 3, 6, 9, 12, 18, 24 and 36 months under the pharmacopoeia and ICH framework, and zero, 1, 3, 6, 9, 12, 18 and 24 months for biological products. Samples are held in an independent stability area in market-equivalent packaging, managed by a dedicated person, with original chromatograms and audit trails retained. After expiry, retention practice follows the finished-product rule: at least one year after expiry, plus any statutory period. Original records support shelf-life estimation through regression and confidence intervals rather than a single indicator.

What is mean kinetic temperature

Mean kinetic temperature is a single equivalent constant temperature computed from the Arrhenius equation across temperature segments, weighted by dwell time and activation energy, commonly 83.144 kJ per mole and adjustable by product. It expresses the cumulative thermal effect on degradation during short-term excursions such as summer transport, cold-room door opening and loading exposure. It bridges short-term deviation data to long-term stability results so the company can decide whether a supplemental study is needed. It does not cover light, humidity, freeze-thaw, vibration or shear, and it cannot release a lot on its own. The mean kinetic temperature conclusion must be combined with product stability data into a written impact assessment.

How to define a starting material

A starting material is a structural fragment that affects critical quality attributes, or the product of an upstream key step in the synthesis route. It must be defined with a clear route and impurity profile, and justified under ICH Q11. Standards rest on the Chinese Pharmacopoeia 2025 edition with ICH Q6A and Q6B, plus registration and internal standards where the internal layer tightens key items with written justification. Test items cover appearance, identification, assay, related substances, residual solvents, elemental impurities, genotoxic impurities and microbial limits, with crystal form and particle size added where needed. Analytical methods are validated for specificity, accuracy, precision, linearity, range, detection and quantitation limits, and robustness.

What stability conditions does ICH require

The pharmacopoeia and ICH framework sets long-term conditions at 25 degrees Celsius and 60 percent relative humidity, intermediate at 30 degrees Celsius and 65 percent relative humidity by stability category, and accelerated at 40 degrees Celsius and 75 percent relative humidity. Refrigerated products add 5 degrees Celsius and 25 degrees Celsius at 60 percent relative humidity. Sampling points are zero, 3, 6, 9, 12, 18, 24 and 36 months with SOP-set windows. Biological products use long-term at 5 plus or minus 3 degrees Celsius and accelerated at 25 plus or minus 2 degrees Celsius, with points at zero, 1, 3, 6, 9, 12, 18 and 24 months. Forced degradation under light, heat, moisture, oxidation and acid or alkaline hydrolysis validates the stability-indicating method.

How does real-time release testing work

Real-time release testing decides lot release from a combination of process and quality data instead of waiting for full end-of-line testing. The decision model needs sufficient batch and stability data as support, and stability samples must stay traceable to release data. Under 21 CFR 211.170, retention data feed the annual stability commitment and the annual report with out-of-specification and out-of-trend summaries. Real-time release is only as strong as its data history, so the method and model must be checked against current regulator guidance rather than expired clauses.

What does biological product stability testing cover

Biological product stability testing covers drug substance and drug product made by biotechnology: proteins, peptides, antibodies and vaccines. Potency is the core item, supported by purity, aggregates and charge variants. Conditions are long-term at 5 plus or minus 3 degrees Celsius and accelerated at 25 plus or minus 2 degrees Celsius, with points at zero, 1, 3, 6, 9, 12, 18 and 24 months. Protein aggregation is irreversible and freeze-thaw cycles must be validated. Potency methods vary widely, so sufficient sample size and statistical determination are required, and the reference standard is stored in the same batch under the same conditions and monitored in parallel.